Pfizer Inc. (NYSE:PFE) Holdings Decreased by Stone House Investment Management LLC


Share on StockTwits

Stone House Investment Management LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 11.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,295 shares of the biopharmaceutical company’s stock after selling 790 shares during the quarter. Stone House Investment Management LLC’s holdings in Pfizer were worth $232,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Sowell Financial Services LLC grew its stake in Pfizer by 5.1% during the 4th quarter. Sowell Financial Services LLC now owns 309,093 shares of the biopharmaceutical company’s stock worth $11,378,000 after buying an additional 15,071 shares during the last quarter. Sound Income Strategies LLC lifted its holdings in shares of Pfizer by 34.5% in the fourth quarter. Sound Income Strategies LLC now owns 119,776 shares of the biopharmaceutical company’s stock valued at $4,409,000 after buying an additional 30,750 shares during the period. Kore Private Wealth LLC lifted its holdings in shares of Pfizer by 6.6% in the third quarter. Kore Private Wealth LLC now owns 18,759 shares of the biopharmaceutical company’s stock valued at $688,000 after buying an additional 1,167 shares during the period. Burns J W & Co. Inc. NY lifted its holdings in shares of Pfizer by 7.0% in the fourth quarter. Burns J W & Co. Inc. NY now owns 99,311 shares of the biopharmaceutical company’s stock valued at $3,656,000 after buying an additional 6,514 shares during the period. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its holdings in shares of Pfizer by 44.4% during the third quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 38,658 shares of the biopharmaceutical company’s stock valued at $1,419,000 after purchasing an additional 11,890 shares during the last quarter. Institutional investors and hedge funds own 69.08% of the company’s stock.

NYSE:PFE opened at $36.86 on Thursday. Pfizer Inc. has a 12-month low of $27.88 and a 12-month high of $43.08. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $204.88 billion, a P/E ratio of 14.63, a P/E/G ratio of 3.10 and a beta of 0.66. The stock’s fifty day simple moving average is $38.25 and its 200-day simple moving average is $37.19.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.01. The firm had revenue of $12.13 billion for the quarter, compared to analyst estimates of $12.30 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The company’s revenue for the quarter was down 4.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.84 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 5th. Investors of record on Friday, January 29th will be given a $0.39 dividend. The ex-dividend date is Thursday, January 28th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 4.23%. This is an increase from Pfizer’s previous quarterly dividend of $0.38. Pfizer’s payout ratio is currently 51.53%.

Several research analysts recently weighed in on the company. Barclays upped their price target on Pfizer from $35.00 to $37.00 and gave the company an “equal weight” rating in a research report on Friday, December 4th. BidaskClub lowered Pfizer from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 31st. Royal Bank of Canada set a $42.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Monday, January 4th. Atlantic Securities lowered Pfizer from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $44.00 to $39.00 in a research report on Monday, October 12th. Finally, Mizuho upped their price target on Pfizer from $43.00 to $44.00 and gave the company a “buy” rating in a research report on Tuesday, November 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $39.87.

In other Pfizer news, major shareholder Pfizer Inc purchased 1,200,000 shares of the stock in a transaction on Tuesday, October 27th. The shares were purchased at an average price of $10.00 per share, with a total value of $12,000,000.00. Following the completion of the transaction, the insider now directly owns 27,349,211 shares in the company, valued at $273,492,110. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.08% of the stock is owned by insiders.

About Pfizer

Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.

Further Reading: What is meant by holder of record?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.